In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College in Tianjin, China, on his latest article published in Blood titled "<a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2026033577">Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia</a>." In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received a course of venetoclax combined with pediatric-inspired chemotherapy, to determine the results of this treatment on MRD negativity.

In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College in Tianjin, China, on his latest article published in Blood titled "Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia." In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received a course of venetoclax combined with pediatric-inspired chemotherapy, to determine the results of this treatment on MRD negativity.

In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College in Tianjin, China, on his latest article published in Blood titled "<a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2026033577" rel="noopener noreferrer">Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia</a>." In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph− ALL received a course of venetoclax combined with pediatric-inspired chemotherapy, to determine the results of this treatment on MRD negativity.

Dose Makes the Cure: Venetoclax in Ph- ALL

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Mariateresa Fulciniti and Angelo D'Alessandro on their latest articles published in Blood. Dr. Fulciniti, of the Dana Farber Cancer Institute, discusses the development of "<a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2026033819">PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma</a>" starting from the question, "Is 17P loss simply a prognostic marker, or does it create specific vulnerabilities that we can therapeutically exploit?" Then, Dr. D'Alessandro, of the University of Colorado, discusses "<a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2025032915">The red blood cell proteome and interactome identify a Band 3–BLVRB axis regulating hypoxic metabolic adaptation</a>." His team began by asking, "What's in a red blood cell? How many proteins are there, and how can we confidently claim that these now several 1000s of proteins in opposite excess are indeed proteins within red blood cells are not coming from contaminants?" Both studies describe how deep molecular profiling can uncover specific, potentially targetable biological dependencies or interaction axes that may enable more precise, mechanism‑based therapeutic strategies.

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Mariateresa Fulciniti and Angelo D'Alessandro on their latest articles published in Blood. Dr. Fulciniti, of the Dana Farber Cancer Institute, discusses the development of "PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma" starting from the question, "Is 17P loss simply a prognostic marker, or does it create specific vulnerabilities that we can therapeutically exploit?" Then, Dr. D'Alessandro, of the University of Colorado, discusses "The red blood cell proteome and interactome identify a Band 3–BLVRB axis regulating hypoxic metabolic adaptation." His team began by asking, "What's in a red blood cell? How many proteins are there, and how can we confidently claim that these now several 1000s of proteins in opposite excess are indeed proteins within red blood cells are not coming from contaminants?" Both studies describe how deep molecular profiling can uncover specific, potentially targetable biological dependencies or interaction axes that may enable more precise, mechanism‑based therapeutic strategies.

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Mariateresa Fulciniti and Angelo D'Alessandro on their latest articles published in Blood. Dr. Fulciniti, of the Dana Farber Cancer Institute, discusses the development of "<a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2026033819" rel="noopener noreferrer">PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma</a>" starting from the question, "Is 17P loss simply a prognostic marker, or does it create specific vulnerabilities that we can therapeutically exploit?" Then, Dr. D'Alessandro, of the University of Colorado, discusses "<a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2025032915" rel="noopener noreferrer">The red blood cell proteome and interactome identify a Band 3–BLVRB axis regulating hypoxic metabolic adaptation</a>." His team began by asking, "What's in a red blood cell? How many proteins are there, and how can we confidently claim that these now several 1000s of proteins in opposite excess are indeed proteins within red blood cells are not coming from contaminants?" Both studies describe how deep molecular profiling can uncover specific, potentially targetable biological dependencies or interaction axes that may enable more precise, mechanism‑based therapeutic strategies.

Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome

In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro and in-vivo data demonstrate enhanced therapeutic efficacy when a CD20-directed bispecific antibody is given in combination with CD19-directed CAR-T cells. Finally, we'll hear about determinants of outcome in NPM1-mutated AML. In a large series of patients with NPM1-mutated AML, investigators identified several variables beyond FLT3-ITD that adversely impacted outcomes. Featured Articles:<ul><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2023022235">Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individuals</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024024310">Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2023022682">CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models</a></li></ul>

In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro and in-vivo data demonstrate enhanced therapeutic efficacy when a CD20-directed bispecific antibody is given in combination with CD19-directed CAR-T cells. Finally, we'll hear about determinants of outcome in NPM1-mutated AML. In a large series of patients with NPM1-mutated AML, investigators identified several variables beyond FLT3-ITD that adversely impacted outcomes. Featured Articles:Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individualsMolecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLCD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro and in-vivo data demonstrate enhanced therapeutic efficacy when a CD20-directed bispecific antibody is given in combination with CD19-directed CAR-T cells. Finally, we'll hear about determinants of outcome in NPM1-mutated AML. In a large series of patients with NPM1-mutated AML, investigators identified several variables beyond FLT3-ITD that adversely impacted outcomes. Featured Articles:<ul><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2023022235" rel="noopener noreferrer">Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individuals</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2024024310" rel="noopener noreferrer">Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML</a></li><li><a href="https://ashpublications.org/blood/article-lookup/DOI/10.1182/blood.2023022682" rel="noopener noreferrer">CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models</a></li></ul>

Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML

The topics in this episode include studies on the mechanism of progression in myelodysplastic syndromes, the value of gait speed as a predictor of outcomes in older adults with hematologic malignancies, the role of extended eltrombobag therapy on severe aplastic anemia, and the role of the Hedghog pathway mutations in chronic lymphocytic leukemia.

Sneak Peek Episode 4

The article highlighted in this trailer "<a href="https://ashpublications.org/blood/article/133/23/2495/273845/The-chromatin-binding-protein-Phf6-restricts-the">The chromatin-binding protein Phf6 restricts the self-renewal of hematopoietic stem cells</a>"  was published June 6, 2019; Blood, Volume 133, Issue 23. The authors of this article are: Satoru Miyagi , Patrycja Sroczynska , Yuko Kato , Yaeko Nakajima-Takagi , Motohiko Oshima , Ola Rizq , Naoya Takayama , Atsunori Saraya , Seiya Mizuno , Fumihiro Sugiyama , Satoru Takahashi , Yumi Matsuzaki , Jesper Christensen , Kristian Helin , Atsushi Iwama.

The article highlighted in this trailer "The chromatin-binding protein Phf6 restricts the self-renewal of hematopoietic stem cells" was published June 6, 2019; Blood, Volume 133, Issue 23. The authors of this article are: Satoru Miyagi , Patrycja Sroczynska , Yuko Kato , Yaeko Nakajima-Takagi , Motohiko Oshima , Ola Rizq , Naoya Takayama , Atsunori Saraya , Seiya Mizuno , Fumihiro Sugiyama , Satoru Takahashi , Yumi Matsuzaki , Jesper Christensen , Kristian Helin , Atsushi Iwama.

The article highlighted in this trailer "<a href="https://ashpublications.org/blood/article/133/23/2495/273845/The-chromatin-binding-protein-Phf6-restricts-the" rel="noopener noreferrer">The chromatin-binding protein Phf6 restricts the self-renewal of hematopoietic stem cells</a>"&nbsp; was published June 6, 2019; Blood, Volume 133, Issue 23.&nbsp;The authors of this article are: Satoru Miyagi , Patrycja Sroczynska , Yuko Kato , Yaeko Nakajima-Takagi , Motohiko Oshima , Ola Rizq , Naoya Takayama , Atsunori Saraya , Seiya Mizuno , Fumihiro Sugiyama , Satoru Takahashi , Yumi Matsuzaki , Jesper Christensen , Kristian Helin , Atsushi Iwama.

Blood Podcast - Trailer

Stay up to date on the latest research and reviews for both clinical and basic hematology with Blood podcast, published weekly in conjunction with each issue of Blood. Additionally, Blood review series podcasts feature in depth discussion with authors of recently published review articles. Subscribe and never miss a new episode.

Share Blood Podcast

Sign up to save your podcasts

Blood Podcast

Blood Podcast episodes

About Blood Podcast

More shows like Blood Podcast

TED Talks Daily

JAMA Editors' Summary

NEJM This Week

JAMA Clinical Reviews

Hematologic Oncology Update

The Hematologist

Core IM | Internal Medicine Podcast

VJHemOnc Podcast

Harrison's PodClass: Internal Medicine Cases and Board Prep

The Curious Clinicians

EHA Unplugged

Blood Cancer Talks

Two Onc Docs

WolverHeme Happy Hour

HemeTalks: Conversations in Hematology Education